Rainbow Childrens Medicare Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹445Cr
- +11.8% YoY
- 0% QoQ
- Net profit
- ₹74Cr
- +7.2% YoY
- −2.6% QoQ
- Margin
- 33%
- −1 pp YoY
- 0 pp QoQ
Guidance rank: #13 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
The company targets an 18% revenue CAGR over the medium term, with a four-year CAGR of about 17-18%. Rainbow Children's Medicare targets a medium-term revenue CAGR of around 17-18%, with historical delivery in this range.
From Rainbow Childrens Medicare Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company targets an 18% revenue CAGR over the medium term, with a four-year CAGR of about 17-18%. (Page 17)
- Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. (Page 6)
- Organic growth is currently mid-single digits; recovery expected in FY27 and FY28. (Page 17)
- Expansion plans include operationalizing more beds at Guwahati soon and scaling mature clusters like Andhra Pradesh, Chennai, and Bangalore. (Pages 11, 17, 19)
- Digital initiatives and marketing ramp-up are expected to boost sales over the next 1-2 years. (Page 19)
2 more points from Rainbow Childrens Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Rainbow Childrens Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company invested INR 57 crores in capex during the quarter to expand and enhance services at existing and upcoming hospitals.
- Significant capital expenditure planned for evolving into a “digital front-door” hospital model, enhancing digital user experience with revamped website, patient app, doctor interfaces, and full EMR ecosystem.
- Expansion planned with additional beds at Visakhapatnam (50 beds) and Guwahati in early next financial year.
- Ongoing investments in hospital projects with a pipeline of bed additions expected over the next 18-24 months.
- Focus on building digital ecosystem and marketing initiatives to drive volume and occupancy growth.
2 more points from Rainbow Childrens Medicare Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Rainbow Childrens Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Rainbow Childrens Medicare Ltd's call on order book
Create a free account to keep reading this call
Rainbow Childrens Medicare Ltd — Quarterly revenue & net profit
Rainbow Childrens Medicare Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 445 | 398 | +11.8% | 445 | 0% |
| Operating profit (EBITDA) | 147 | 134 | +9.7% | 149 | -1.3% |
| Operating margin | 33% | 34% | -1 pp | 33% | 0 pp |
| Profit before tax | 98 | 94 | +4.3% | 102 | -3.9% |
| Net profit (PAT) | 74 | 69 | +7.2% | 76 | -2.6% |
| EPS (₹) | 7.14 | 6.76 | +5.6% | 7.41 | -3.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹548 Cr, net profit ₹84 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Rainbow Childrens Medicare's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Krishna Institute of Medical Sciences (Q3 FY26)
Hospitals like Kondapur to see 20-25% year-on-year growth post new facility commissioning (Pg.18). Key concall takeaways from Krishna Institute of Medical…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Rainbow Childrens Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Rainbow Childrens Medicare Ltd Q3 FY26 results?
The company targets an 18% revenue CAGR over the medium term, with a four-year CAGR of about 17-18%. Rainbow Children's Medicare targets a medium-term revenue CAGR of around 17-18%, with historical delivery in this range.
What is Rainbow Childrens Medicare Ltd share price analysis?
Rainbow Childrens Medicare Ltd currently shows a neutral. The stock trades at a P/E of 56.7 with a market cap of ₹16,236 Cr. Investors should review the full earnings analysis for detailed insights.
Is Rainbow Childrens Medicare Ltd planning capital expenditure?
The company invested INR 57 crores in capex during the quarter to expand and enhance services at existing and upcoming hospitals.
Keep Rainbow Childrens Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
